skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

Safety and efficacy of entecavir for the treatment of chronic hepatitis B

Review

(1767) Views  (582) Full article downloads

Authors: Melissa Osborn

Published Date February 2011 Volume 2011:4 Pages 55 - 64
DOI: http://dx.doi.org/10.2147/IDR.S4188

Melissa Osborn
Department of Medicine, Division of Infectious Diseases, Emory University School of Medicine, Atlanta, GA, USA

Abstract: Entecavir is a cyclopentyl deoxyguanosine analog that was approved for the treatment of the hepatitis B virus (HBV) in 2005. In Phase III trials, it showed potent HBV suppression with drops of 6- to 7-log copies/mL in HBV DNA at 1 year. In addition, rates of genotypic resistance in nucleos(t)ide-naïve patients are low, reaching only 1.2% after 6 years. Safety and efficacy have been established in compensated cirrhosis and HIV-coinfected patients. Studies in decompensated cirrhosis also show efficacy. Because of potent viral suppression and a large genetic barrier to resistance, entecavir is now a first-line choice in most HBV treatment guidelines and has become an integral part of the HBV treatment armamentarium.

Keywords: hepatitis B, therapy, entecavir




 

Other articles by Dr Melissa Osborn



Readers of this article also read:

The determinants of the antibiotic resistance process
Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors
Tenofovir: A new option for the treatment of chronic hepatitis B
Occult hepatitis B virus infection in Egyptian hemodialysis patients with or without hepatitis C virus infection
Current treatment of choice for chronic hepatitis C infection
A cost-effectiveness analysis of different therapies in patients with chronic hepatitis B in Italy
Boceprevir in the treatment of chronic hepatitis C virus infection
Cumulative clinical experience from over a decade of use of levofloxacin in community-acquired pneumonia: critical appraisal and role in therapy
Cytomegalovirus retinitis treated with valganciclovir in Wegener’s granulomatosis
High prevalence of extended-spectrum β-lactamase-producing pathogens: results of a surveillance study in two hospitals in Ujjain, India
  • Testimonials

    "... I was impressed at the rapidity of publication from submission to final acceptance." Dr Edwin Thrower, PhD, Yale University